타이틀

John has served as the Chief Executive Officer of Genosco since its inception in 2008. He brings over 40 years of pharmaceutical and R&D experience, during which time his work has led to the identification, development and approval of multiple drug candidates for the treatments of cancer and diabetes.
At Genosco, he has led the research and development of all new drug candidates, including Lazertinib. Prior to joining Genosco, he served as the head of the Anti-Cancer Research Center at Korea Research Institute of Chemical Technology (KRICT). Prior to KRICT, he served in various roles at LG Life Sciences, most notably as the Principle Inventor of Zemiglo for treatment of Diabetes (as of 2020, Zemiglo was the top selling made-in-Korea drug). During his 16 year tenure at LG, he was also deeply involved in building core drug development platforms such as High Throughput Screening, Focused Chemical Library and Peptidomimetic Design. Prior to LG, he served as Senior Research Associate at The Scripps Research Institute and Visiting Scholar in Combinatorial Chemistry at UC Berkley.
He earned his B.S. in Chemistry Education from Seoul National University, M.S. in Photochemistry from Korea Advanced Institute of Science and Technology (KAIST) and Ph.D. in Bio-organic Chemistry in Caltech.

Steve has served as the CEO of Genosco since 2023 and brings over 20+ years of experience in clinical R&D and general management.
Before joining Genosco in 2015 as CSO, he served as the CTO of Oscotec, overseeing all aspects of discovery and clinical research and development of drug candidates for the treatment of cancer and autoimmune diseases.
Particularly, he led discovery, pre-clinical and clinical development of an autoimmune disease drug candidate, Cevidoplenib (SKI-O-703), and cancer drug candidate, SKI-G-801. He also served as a Professor at Dankook University. He earned his B.S. and M.S. from Seoul National University School of Dentistry, and Ph.D. in Pharmacology from Seoul National University.

Kevin joined Genosco in 2008 and currently serves as the Chief Financial Officer overseeing all finance, operations and related activities such as accounting, investments, taxes, human resources and business development. He previously served in various financial and management positions including the Business Development Director of Oscotec and CFO of KleanColor.
He earned his B.S. in Communication from Seoul National University.

Young Chun Jung joined Genosco as Vice President in 2023, bringing over 30+ years of experience in CMC and Process Development. Previously he served as Director at Mersana Therapeutics and Akebia Therapeutics as well as in various positions at Vertex Pharmaceuticals and SK Corporation. He earned his B.S. and M.S. from Seoul National University, and his Ph.D. in Organic Chemistry from University of South Florida.

Jaekyoo has served at Genosco since its inception and has been its key member overseeing research and development of all new drug candidates to date, including Lazertinib. Prior to joining Genosco he served many years at LG Life Sciences and ArQule (acquired by Merck).
He earned his Ph.D. in Chemistry from Johns Hopkins and completed post-doc fellowship at The Scripps Research Institute.

Anu joined Genosco in 2021, bringing over 20+ years of experience in cancer with expertise in kinase discovery programs. Previously she served as Associate Director at Black Diamond Therapeutics and Principle Investigator, Biology at Deciphera Pharmaceuticals.
She earned her Ph.D. in Life Sciences from Jawaharlal Nehru University in New Delhi and completed post-doc fellowships at California Pacific Medical Center Research Institute and Stanford University.